Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Nbi Biosciences Pvt Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and a distinct art unit. The focused nature of this prosecution suggests a specific pharmaceutical application is currently under review. This concentration allows the company to dedicate its resources to a single point of interaction with the patent office.
Abraham, Amjad A is the busiest examiner for the portfolio, overseeing the pending office action. Because there is only the mentioned pending action in total, this examiner is responsible for the company's entire active office action workload. This concentration allows for a targeted strategy focused on the preferences of a single examiner and art unit. Practitioners should evaluate the examiner's historical allowance rates and common rejections within this specific art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABRAHAM, AMJAD A | 1 | 31.7% | +35.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18687872 | PLANT-DERIVED NEUROPROTECTIVE COMPOSITION AND A METHOD OF MANUFACTURING THE SAME | ABRAHAM, AMJAD A | 54d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18687872 | PLANT-DERIVED NEUROPROTECTIVE COMPOSITION AND A METHOD OF MANUFACTURING THE SAME | ABRAHAM, AMJAD A | 54d |
| Art Unit | Apps |
|---|---|
| 1663 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18687872 | PLANT-DERIVED NEUROPROTECTIVE COMPOSITION AND A METHOD OF MANUFACTURING THE SAME | ABRAHAM, AMJAD A | 1663 | §102§103§112 | Non-Final OA | 54d | Pending | Feb 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial